Lineage Cell Therapeutics Stock Price

0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 206,168
Bid Price
Ask Price
News -
Day High 1.62


52 Week Range


Day Low 1.48
Company Name Stock Ticker Symbol Market Type
Lineage Cell Therapeutics Inc LCTX AMEX Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 1.55 16:17:26
Open Price Low Price High Price Close Price Prev Close
1.54 1.48 1.62 1.57 1.55
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,519 206,168 $ 1.57 $ 323,804 - 1.10 - 2.80
Last Trade Time Type Quantity Stock Price Currency
20:00:00 887 $ 1.57 USD


Draw Mode:

Lineage Cell Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 232.47M 149.98M 127.27M $ 3.90M $ - -0.26 -5.40
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 394.66k 8.50%

more financials information »

Lineage Cell Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical LCTX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.751.791.471.57684,595-0.20-11.43%
1 Month1.601.791.471.62421,964-0.05-3.13%
3 Months1.241.791.191.46898,5490.3125.0%
6 Months1.501.791.101.40769,3990.053.33%
1 Year2.662.801.101.85844,130-1.11-41.73%
3 Years0.95953.13160.53391.75985,6160.590561.54%
5 Years0.95953.13160.53391.75985,6160.590561.54%

Lineage Cell Therapeutics Description

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, a oligodendrocyte progenitor cell therapy for acute spinal cord injuries and VAC2, a allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer. Its lead cell delivery clinical program is Renevia, an investigational medical device developed as an alternative for whole adipose tissue transfer procedures.

Your Recent History
Lineage Ce..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now